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Abstract: Ionotropic glutamate receptors (iGluRs) mediate the synaptic and metabolic actions of
glutamate. These iGluRs are classified within the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid (AMPA)-type, kainate-type, and N-methyl-D-aspartate (NMDA)-type functional receptor
families. The iGluR assemblies are regulated by transcription, alternative splicing, and cytoplasmic
post-translational modifications. The iGluR subunit proteins are transported from the endoplasmic
reticulum, inserted into the synaptic membranes, and anchored at their action site by different
scaffolding and interacting proteins. The functional properties of iGluRs depend on their subunit
composition, the amino acid sequence of the protein domains, and the scaffolding proteins in
the synaptic membranes. The iGluRs are removed from the membranes by enzymatic action and
endocytosis. Hippocampal iGluRs are rearranged through the upregulation and downregulation of
the subunits following deafferentation and epileptic seizures. The rearrangement of iGluRs and the
alteration of their subunit composition transform neurons into “pathological” cells, determining the
further plasticity or pathology of the hippocampal formation. In the present review, we summarize
the expression of AMPA, kainate, and NMDA receptor subunits following deafferentation, repeated
mild seizures, and status epilepticus. We compare our results to literature descriptions, and draw
conclusions as to the reactive plasticity of iGluRs in the hippocampus.
Keywords: AMPA receptor; kainate receptor; NMDA receptor; hippocampus; epilepsy; glutamate;
neuronal plasticity
1. Introduction
Glutamic acid (Glu) is the main excitatory neurotransmitter in the mammalian brain. Neurons,
astrocytes, and probably other glial cells use Glu for information processing [1,2]. Interneuronal
synapses use glutamate as a transmitter amino acid and as an extracellularly diffusing neuromodulator
targeting both presynaptic and postsynaptic structures [1–3]. Glu is released primarily from
synaptic vesicles into the synaptic cleft. Glu diffuses fast from the synaptic cleft, partly affecting
the receptors of the presynaptic membrane, and partly reaching the receptors of the postsynaptic
membrane [3]. In the short term, the activation of ionotropic glutamate receptors (iGluRs) causes
membrane depolarization/excitation through cation influx [1,3]. Long-term synaptic plasticity effects
include conformational, localizational, qualitative, and quantitative changes of the presynaptic and
postsynaptic iGluRs, the anchoring macromolecules, and molecular aggregates [3,4]. The gene
expression alterations of the cell nucleus caused by the iGluR signaling will be mediated by
synapto-nuclear protein messengers inside the neuron [5].
The short-term and long-term synaptic effects of Glu are mediated by ionotropic and metabotropic
Glu receptors (iGluRs and mGluRs) [1,3,6]. The iGluRs are cation channels that open when Glu is
bound to their extracellular loop [1,3,6]. The mGluRs are not conducting ion fluxes when they bind Glu;
instead, they mediate intracellular biochemical processes through G-proteins (which may target ion
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channels, too) [1,6]. The iGluRs mediate synaptic facilitation and depression, long-term potentiation
(LTP), and long-term depression (LTD), which are underlying the cellular processes of learning in the
brain [1,7]. The strong and sustaining release of Glu is responsible for excitotoxicity in the brain [8,9].
The excitotoxic effects of Glu are manifested as neuronal shrinkage, mitochondrial vacuolization,
neuronal cell death with concomitant astroglial swelling, microglial activation, and the sprouting of
microvessels [8–10]. There are extensive reviews in the literature discussing the functional significance
of the iGluRs in neuronal plasticity [11] and neurotoxic damage [9]. The present review focuses on the
iGluR family members, treating the possible alterations of the subunit composition of the ionotropic
receptors in animal epilepsies. The author’s own results cited in this review were presented in five in
extenso publications [12–15] and in one congress report [16].
2. Types of iGluRs in the Mammalian Brain
The excitatory neurotransmission in the central nervous system (CNS) is largely maintained
by Glu; therefore, the grey matter of the rodent brain contains high amount of iGluRs (Figure 1).
There are three main structurally and pharmacologically different iGluR classes in the adult mammalian
brain: α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, kainate receptors,
and N-methyl-D-aspartate (NMDA) receptors [1,3,6]. Apart from these major iGluRs, there are some
ill-characterized “delta” type or “orphan” receptors (GluD1 and GluD2), which share structural
homology to AMPA and kainate receptors; however, they are not gated by Glu, and do not function
as cation channels. Instead, they connect presynaptic and postsynaptic elements with the help of
an extracellular glycoprotein [17].
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Figure 1. Histoblot images displaying the localization of the α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) receptor subunits GluA1-4 and GluA2 in the rat brain: GluA1-4 (A), GluA2 
(B); the kainate receptor subunit GluK5 (C), and the N-methyl-D-aspartate (NMDA) receptor subunit 
GluN1 (D). Note the strong anti-GluA1-4 and anti-GluN1 staining of the dentate molecular layer; the 
stratum oriens (SO), stratum radiatum (SR), stratum lacunosum (SL), and stratum moleculare (SM) 
of the Ammon’s horn. The anti-GluK5 serum stains the stratum lucidum (SLUC) of CA3 strongly (C). 
The staining density of the dentate fascia and the SO in CA1 is medium (C). The granular and 
pyramidal layers display weak GluN1 immunoreactivity (D). The histoblot signal of the GluA2 
Figure 1. Histoblot images displaying the localization of the α-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA) receptor subunits GluA1-4 and GluA2 in the rat brain: GluA1-4 (A), GluA2
(B); the kainate receptor subunit GluK5 (C), and the -methyl-D-aspartate (NMDA) receptor subunit
GluN1 (D). Note the strong a ti-GluA1-4 anti-GluN1 staining of the dentate molecular layer;
the stratum oriens (SO), stratum radiatum (SR), stratum lacunosum (SL), and stratum moleculare (SM)
of the Ammon’s horn. The anti-GluK5 serum stains the stratum lucidum (SLUC) of CA3 strongly (C).
The staining density of the dentate fascia and the SO in CA1 is medium (C). The granular and pyramidal
layers display weak GluN1 immunoreactivity (D). The histoblot signal of the GluA2 subunit (B) is
similar to that of the GluA1-4, although weaker. We noticed that the CA1 region with anti-GluA2 was
labeled stronger than the rest of the Ammon’s horn (B) [16]. See Appendix A for methods. Bar: 1 cm.
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The iGluRs were named after their selective pharmacological agonists: AMPA receptors (AMPARs)
after the agonist α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate receptors
(KARs) after the agonist kainic acid (KA), which is a toxic glutamate analogue, and NMDA receptors
(NMDARs) after the agonist N-methyl-D-aspartate (NMDA) [1]. The iGluRs are heterotetramers
consisting of four transmembrane proteins with a large extracellular ligand-binding domain, a common
pore-forming transmembrane domain, and an intracellular C-terminal domain: these transmembrane
proteins are the receptor subunits [1,3,18]. The subunits are structurally different: the peptide
sequences of the extracellular domains are frequently used for the generation of antibodies in
immunohistochemistry [1]. The transmembrane domains of the four subunits build up the pore
of the ion channel [1,6]. The intracellular C-terminal domain is important for connecting the
receptor to scaffolding proteins [1,6]. The AMPA receptor has four subunits named GluA1,
GluA2, GluA3, and GluA4 [18]. Kainate receptor (KAR) subunits are called GluK1, GluK2, GluK3,
GluK4, and GluK5 [18]. The NMDA receptor has seven subunits named GluN1, GluN2A, GluN2B,
GluN2C, GluN2D, GluN3A, and GluN3B [18]. The subunits are coded by corresponding genes:
the AMPA subunit genes are named GRIA1, GRIA2, GRIA3, and GRIA4, the kainate subunit genes
are accordingly GRIK1, GRIK2, GRIK3, GRIK4, and GRIK5, and the NMDA subunit genes are called
GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, and GRIN3B [18]. The acronyms of the
subunit proteins and genes are official terms created by the International Union of Basic and Clinical
Pharmacology (IUPHAR) [18]. The receptor tetramers are formed through the assembly of four, mainly
different receptor subunit proteins [1,3,6,18]. There are multiple subunit variants due to the alternative
splicing and editing of the RNA transcripts; these are listed in more comprehensive reviews [1].
2.1. Tissue Localization of iGluRs and Subunits in the Hippocampus
2.1.1. AMPA Receptors and Subunits
Several immunohistochemical studies have described the hippocampal localization of the
iGluRs [19–25]. These studies have described the widespread occurrence of AMPARs in pyramidal
neurons [19,20,22] and interneurons [23–25]. The early descriptions utilizing immunoperoxidase
methods [19,20,22] and subcellular fractionation [26] indicated the postsynaptic localization of the
receptor proteins.
The application of the subunit-specific antibodies to GluA1, GluA2, and GluA3 in histoblotting
provided similar immunostaining, and also made the semiquantitative densitometry of the subunit
proteins in the histoblots possible [12–14]. The histoblotting method omits tissue fixation: the brains
are rapidly frozen in isopentane and then sectioned with cryostat; then, the sections are melted onto
microscope slides, and the proteins of the sections are transferred to nitrocellulose membranes [12,13].
The detection of the subunit proteins with antibodies is done on the nitrocellulose membranes,
which are incubated with the subunit-specific antibodies, and alkaline phosphatase-conjugated
secondary antibodies [12,13]. The signal is detected through the visualization of the enzyme
activity [12,13]. These histoblots did not give us cellular details, but instead displayed the distribution
and density of the receptor subunit protein precisely in the different layers and areas of the
hippocampus (Figure 1). Therefore, histoblots were suitable for the semiquantitative detection of the
alterations of subunit protein expression in the hippocampus [12–14]. The strongest immunostaining
has been observed with the pan-AMPA antibody, which is reacting with every subunit of the
AMPAR [27,28]; the GluA1 antibodies stain with medium density [12–14], whereas the GluA2 antibody
results in a weaker signal (Figure 1). The GluA1flop antibody stains similarly to GluA1, but gives
a weaker signal [12]. Antibodies stain mainly the neuropil: the most intense staining is experienced
in the stratum oriens (SO), stratum radiatum (SR), and stratum lacunosum (SL) of the CA1 region.
The least intense staining is found in the hilus of the dentate fascia and in the SR and stratum lucidum
(SLUC) of CA3 [12,13]. Frozen sections from perfusion-fixed mouse brains stained with GluA2/3
Int. J. Mol. Sci. 2019, 20, 1030 4 of 17
antibodies [15] have also stained several multipolar neurons in the hilus of the dentate fascia, in which
the neurons were supposedly the hilar mossy cells [15,24,29].
2.1.2. Kainate Receptor Subunits
The application of the histoblotting procedure for the detection of the GluK5 subunit resulted in
a homogeneous neuropil staining in SO, SR, stratum lacunosum (SL), and stratum moleculare (SM) in
the mouse and rat hippocampus (Figure 1). We detected strikingly strong GluK5 immunostaining in
the stratum lucidum (SLUC) of CA3 (Figure 1C). This strong immunostaining of the SLUC in CA3
was characteristic of the histoblotting procedure, and precisely depicted the area where the mossy
fibers form giant synapses (Figure 1C). This strong immunostaining of the CA3 SLUC layer has not
been detected with GluK2 antibody applied on frozen sections from perfusion fixed mouse brains [15].
The immunohistochemical localization of GluK1 in histological sections of the mouse hippocampus
displayed punctate immunostaining of the neuropil in the SR, and immunoreactivity of the CA3
pyramidal cell bodies and dendrites in the SLUC and SR of the CA3 (Figure 2A). The GluK2 antibody
stained the cytoplasm of the CA3 neurons in mice [15] (Figure 2B). The strong GluK5 signal originating
from the SLUC of the CA3 in histoblots (Figure 1C) suggested precise target localization, because the
staining strictly corresponded to the area occupied by the mossy fiber axon terminals [13,15,16]. Indeed,
GluK5 and GluK2 were localized in immunohistochemical sections [30] similarly to our histoblots:
strong staining of the SLUC was detected in the CA3, which was not seen in the GluK4/5 knockout
mice [30]. This strong immunostaining originated from the synaptic KAR content of the mossy fiber
CA3 pyramidal cell synapses as observed also with immunoelectron microscopy of KAR-specific
scaffolding proteins [30].
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2.1.3. NMDA Receptor Subunits 
Histoblotting with the anti-GluN1 serum revealed a laminar staining pattern in the 
hippocampus, which was similar to the AMPAR immunostaining (Figure 1). The most intense 
neuropil staining has been found in the SO, SR, and SL of the CA1 [12,13,15]. The staining of these 
layers was slightly increasing toward the subiculum. Strong immunostaining was experienced in the 
Figure 2. I unohistochemical localization of GluK1 (A) and GluK2 (B) antibodies in the CA3 region
of the murine hippocampus. The immunohistochemical picture suggests mainly postsynaptic GluK1
and GluK2 localization. PYR: pyramidal layer; LUC: stratum lucidum; RAD: stratum radiatum. Arrows
on Figure 2A point to unstained mossy fiber terminals. See Appendix A for methods. Bars: 50 µm.
2.1.3. NMDA Receptor Subunits
Histoblotting with the a ti-GluN1 serum revealed a laminar staining pattern in the hippocampus,
which was similar to the AMPAR immunostaining (Figure 1). The most intense neuropil staining
has been found in the SO, SR, and SL of the CA1 [12,13,15]. The staining of these layers was slightly
increasing toward the subiculum. Strong immunostaining was experienced in the stratum moleculare
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(SM) of the dentate fascia, whereas weak staining was observed in the hilus, SM, SR, and SLUC of CA3,
and in the pyramidal cell and granule cell layers [12,13,15]. The histoblots prepared with anti-GluN2A
and anti-GluN2B sera stained the CA1 and the molecular layer of the dentate fascia similarly to the
staining of the GluN1 serum, but with weaker signal [12,13]. Light microscopic immunohistochemistry
with GluN1, GluN2A, and GluN2B antibodies have mainly stained the synaptic layers of the CA1 and
the entire dentate molecular layer [15,21,28]. The localization of GluN3 subunits in the hippocampus
also proved the ubiquitous neuronal localization pattern [31].
2.1.4. Rearrangement of iGluR Subunits Following Chronic Deafferentation
Destruction of the lateral entorhinal cortex (LEC) with electrocoagulation and suction in rats [12]
has caused characteristic alterations of iGluR subunits in the hippocampus mainly on the side of
the lesion [12]. Forty days following the ablation of the LEC, the GluA1flop decreased in the SO,
SR, SL, and SM of CA1, whilst GluN1, GluN2B, and GluK5 increased in the SL and SM of the
CA1 and SM of the dentate fascia. These were the areas where the excitatory afferents from the LEC
terminated, which were degenerated following the ablation [12]. These results highlight the importance
of the activity of the afferent presynaptic terminals in the maintenance of the postsynaptic iGluR
subunit composition [12]. As to the increase of the GluN2B subunit, the extrasynaptic accumulation
of NMDA receptors or receptor subunits has to be taken into account [12,32]. The extrasynaptic
NMDARs contain a GluN2B subunit and appear in Huntington disease, ischemia, and epilepsy [32].
These extrasynaptic NMDA receptors increase the neurotoxicity of glutamate [32]. The rearrangement
of the hippocampal iGluRs following temporoammonic path afferent degeneration [12] has caused
spatial memory deficiency [33] and attenuated the acute hippocampal seizures in the LEC-ablated
animals [12].
2.2. Electron Microscopic Immunohistochemistry of the iGluR Subunits in Rodent Hippocampus
After the early electron microscopic immunoperoxidase observations, which emphasized the
postsynaptic iGluR localization [19–22], postembedding immunogold electron microscopic studies
revealed both presynaptic and postsynaptic localizations of iGluR subunits in the hippocampus [34].
Electron microscopic localization studies postulated the presence of all four AMPAR subunits in type
1 (asymmetric) synapses in the area of the postsynaptic density [34]. This study also suggested the
presence of AMPARs in some interneurons of the pyramidal layer and alveus of CA1 [34]. GluA1 and
GluA2 subunits have been localized not only postsynaptically, but also in presynaptic axons in
hippocampal slice cultures and young rats [35]. Investigations of KAR localization have revealed that
GluK2 and GluK4/5 subunits were localized both presynaptically [31,36] and postsynaptically [31,36]
in the CA3 mossy fiber synapses. Similar, ultrastructural postsynaptic localization of the GluN1 protein
has been described in asymmetric (type 1) CA1 synapses, indicating the presence of NMDARs in the
postsynaptic densities of excitatory hippocampal synapses [37]. Other studies have also described
labeled postsynaptic densities with the immunoperoxidase method, as well as the localization of the
GluN1 C1 splice variant in presynaptic terminals in the subiculum of the hippocampus in young rats
and thin myelinated axons of the hippocampal fimbria, which may indicate the axonal transport of
the GluN1 C1 subunit protein [21]. The presynaptic presence of iGluRs may refer to their functional
significance and regulatory activity in axon terminals: presynaptic NMDARs and KARs may regulate
the traffic of synaptic vesicles, and may also indicate the exocytosis and endocytosis and the trafficking
of the receptor subunit proteins [4,21,31,36,38,39].
3. Functional Alterations, Expression, and Distribution of iGluR Subunits Following Seizures
Convulsions are states of hyperexcitation in the brain tissue. Forebrain epileptic convulsions are
mediated mainly by Glu [40]. Brain microdialysis detected a significant increase of tissue glutamate
during 4-aminopyridine (4-AP)-induced seizures [41]. The non-competitive antagonist of the AMPA
receptor, GYKI 52466, reduced the seizure symptoms and increased the seizure latency [42,43], but it
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did not prevent the swelling of the hippocampal astrocytes in 4-AP seizures [42]. The pharmacological
antagonists of KARs prevented the acute pilocarpine seizure [44]. The combination of NBQX
(an AMPAR antagonist) and ifenprodil (an NMDAR antagonist) exerted promising antiepileptic
actions in kainate-induced murine epilepsy [45]. Antagonists of NMDAR inhibited the Glu release [46]
and seizure symptoms [43,46], as well as prevented the post-ictal neuronal damage [47] and the
long-term reactive plasticity of the dentate granule cells [45].
The endogenous downregulation of the iGluRs may protect the neurons and the synapses against
the toxic effects of Glu [48]. Neuroprotection in acute epileptic fits against the neurotoxicity of
Glu can be achieved by blocking the iGluRs with pharmacological antagonists [42–49]. However,
the neuronal damage and degeneration, which develop in the chronic seizure, rearrange the wiring
of the brain [45,50]. The loss of the neurons and axon terminal degeneration will change the
expression, localization, and molecular composition of iGluRs, as it could be seen in our previous
experiments: the destruction of the LEC increased GluN1, GluN2B, and GluK5 in the hippocampus [12].
The neuronal loss in CA1 and CA3 during pilocarpine-induced epilepsy significantly increased GluK2
immunoreactivity [15,16]. The neurodegeneration has functional consequences, too. The neuronal
loss in the hippocampus affects not only the wiring but also the functions; learning and memory of
the experimental animals will decrease significantly [12,33]. The consequences of the seizures are
discussed in two sections:
(1) we discuss the alterations of iGluRs following repeated, mild seizures without hippocampal
neuronal degeneration [51,52];
(2) we discuss the alterations of iGluRs following chronic epilepsy and hippocampal neuronal
damage [15,53].
3.1. Alterations of iGluRs after Repeated, Short Convulsions Caused by 4-AP
The acute seizures precipitated by the systemic injection of 4-aminopyridine (4-AP) cause brain
edema and increase of the regional cerebral blood flow (rCBF) [52]. We measured elevated glutamate
concentration in the striatum lasting for more than 60 minutes [41]. Electron microscopy revealed
a slight shrinkage of the neurons [52] and astrocytic swelling [42,52]. The animals successfully
recovered from the seizure [42,51,52], because the systemically injected 4-AP was eliminated from the
blood plasma with a 65 to 71-minute half-life [54]. When we injected the rats daily for 12 days, most
of the animals suffered mild behavioral motor convulsions every day after the injections [13,14,51].
Following the repeated seizures, the animals displayed characteristic alterations of hippocampal
iGluRs: significant decrease of AMPAR density (the density of GluA1-4 subunits) in the dentate
fascia (hilus and molecular layer) and the SO of the CA3. At the same time, GluA1 was slightly, but
significantly, upregulated in the SL and SM of CA1 and the SR and SLUC of CA3 [13]. The density
of GluA2 was dropped significantly in the SO, SL, and SM of CA1 and in the hilus of the dentate
fascia [13]. Accordingly, hippocampal slices from convulsing animals displayed a significant increase
of in vitro cobalt uptake (indicating the increased calcium permeability of non-NMDA receptor
channels [13]) in the SL and SR of CA1 and in the dentate fascia [13]. The histoblotting of GluK5
revealed a significant decrease of the density in SLUC of CA3 [13]. Other areas did not show
alterations in GluK5 density [13]. The density values of GluN1 and GluN2B did not change, whilst the
density values of GluN2A showed significant increases in every layer of the CA1, CA3, and dentate
fascia [13]. The electrophysiological–pharmacological investigations of these hippocampal slices
revealed a significant increase in the basic excitability (increased population spike amplitudes) [13].
The antagonistic effects of GYKI 52466 (AMPAR antagonist [13]) were decreased significantly in the
convulsing animals, indicating the changes in AMPAR subunit composition [13]. The Q/R-edited
GluA2 subunit has a key role in the determination of AMPAR cation permeability, receptor kinetics,
and blockade by endogenous polyamines [13]. We think that the observed reduction of GYKI 52466
sensitivity is consistent with the appearance of GluA2-lacking AMPARs [13]. The upregulation of the
GluN2A subunit exerted no effects on the pharmacological properties of the NMDARs in our slice
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experiments [13], as it was proved that GluN2B was more likely to be responsible for the augmentation
of Glu-induced excitatory activity in epilepsy [38]. The entorhinal cortex of the convulsing rats
displayed similar iGluR subunit alterations and increased excitability [14].
3.2. Alterations of iGluRs after Pilocarpine Seizures and Hippocampal Neuronal Degeneration
These experiments were performed in mice, which were systemically injected with pilocarpine
and developed status epilepticus (SE) in the next 90 minutes [15,16,53]. The surviving animals were
investigated two months after the SE with standard histological and immunohistochemical methods,
including the detection of GluA1, GluA2, GluA3, GluK2, and GluN1 subunit proteins in the dorsal
hippocampus [15]. The hippocampal layers were evaluated through light microscope densitometry
performed on the immunohistochemistry sections [15]. The convulsing animals displayed neuronal
degeneration in the hippocampus: the neuronal loss was not uniform, but it was present in every
hippocampus, consisting of cell loss in CA1 and CA3, as seen with anti-neuron-specific nuclear
protein (anti-NeuN) immunohistochemistry [15]. The following main alterations of iGluRs were
noted in the pilocarpine-treated mice. The significant decrease of the AMPAR subunits GluA1,
GluA2, and GluA3 was always present in the layers of the dentate fascia and SR and SLUC of the
CA3 [15]. Despite this density decrease, the neurons in the pyramidal layer of the Ammon’s horn
and neurons in the hilus of the dentate fascia displayed strong immunostaining with the GluA2/3
antibody [15]. This GluA2/3-like immunostaining was also detected in the granule cell layer of the
dentate fascia [15]. A significant decrease of AMPARs was detected in the SR of the CA1 region [15].
The significant increase of GluK2 was concomitant in the SR (but not in the SLUC) of the CA3
region [15]. The molecular layer and hilus of the dentate fascia also displayed increased density of
immunostaining with GluK2 antibody in the Balb/c mice [15]. The NMRI-strain mice displayed
a significant decrease of GluK2 in the hilus of the dentate fascia [15]. The densities of GluN1 either
decreased (in Balb/c mice) or did not show alteration (in NMRI mice) [15]. A significant increase of
GluN1 immunostaining density was observed in the NMRI mice in the SM and SL of the CA1 [15].
Detectable GluN1 immunostaining was present in the granular layer of the dentate fascia of the control
and the epileptic animals [15]. Upon testing these pilocarpine-treated chronically seizing animals for
learning and memory with the Barnes maze method [55], significantly worse learning and memory
capabilities were measured (unpublished, preliminary results from our laboratory).
4. The Reactive Plasticity of iGluRs in Animal Epilepsies
4.1. AMPA Receptors
Epileptogenesis is associated with enhanced glutamatergic neurotransmission [56]. Glutamate
induces the increase of the cytoplasmic level of free Ca2+, which in turn enhances neuronal and
astrocytic Glu release [57,58]. The intracellular Ca2+ accumulation also triggers molecular cascades
involving several intracellular messenger systems, which finally cause the death of the neuron [9,40].
The activation of the Ca2+-permeable iGluRs initiates cell damage and neuronal death [6,9,40].
The first glutamate receptor with known conductance to Ca2+ was the NMDAR [57]. Later,
it was shown that some AMPARs are also permeable to Ca2+ [59,60]. In AMPARs, the GluA2
subunit is responsible for Ca2+ gating: the GluA2 restricts Ca2+ permeability [59,60]. The GluA2
hypothesis was set in 1997, stating that Ca2+-permeable AMPARs are responsible for cell death in
status epilepticus in experimental animals [59], because it was observed that status epilepticus in adult
rats caused the downregulation of GluA2 (and GluA3) mRNA [59]. Then, in a second phase of this
pathological process, neurons died in the GluA2/3 downregulated area of the hippocampus [59,60].
Region-specific alterations in the phosphorylation of the GluA1 subunit were also detected in rats
with pilocarpine epilepsy [61]. Pilocarpine convulsions caused the changes of serine845 and serine
831 phosphorylation of GluA1 in these animals, and it is known that dephosphorylation of the subunit
is responsible for the desertion of the AMPAR from the synaptic membranes [61]. A decreased
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expression of GluA1 and GluA2 mRNAs was detected in the hippocampus during the first week
following pilocarpine-induced status epilepticus in rats [62,63]. Electrophysiology has revealed
the presence of GluA2-lacking, Ca2+-permeable AMPAR in the pyramidal neurons of epileptic
animals [64]. The presence of Ca2+-permeable AMPARs has also been validated in epileptogenic
human hypothalamic hamartomas [65]. These tumorous patients developed characteristic refractory
seizures, and the electrophysiological investigation of needle-biopsy tumor tissue specimens proved
the presence of Ca2+-permeable AMPARs [65]. Moreover, the RNA analysis of the tissue proved that
the pathological tissues do not contain adenosine deaminase, which is necessary for the Q/R-editing
of GluA2 mRNA [65].
Our experiments and the literature data proved that in epilepsy, the adult neuronal AMPARs
have a greater probability of losing their GluA2 subunit due to downregulation of the subunit protein
and/or the subunit mRNA [13–15,59,60,64,65]. Besides our experiments [13–15], other studies have
also revealed the downregulation of GluA2 [59,60,64,65] and GRIA2 [59] following SE in the cerebral
cortex. The molecular mechanisms of the downregulation of the GluA2 subunit in epilepsy are
not completely understood. Since the hippocampal AMPAR mRNAs are present not only in the
cell body, but also in the dendrites [66], we think that a fast adaptation of the local translational
processes may operate in the downregulation [66]. The phosphorylation of AMPAR subunits could
be also responsible: the phosphorylation–dephosphorylation cycle is responsible for the intracellular
traffic and endocytosis [61,67]. It was shown recently that the phosphorylation of GluA1 alone
induces an increase of the Ca2+-permeability of AMPARs, which probably takes place with the help of
scaffolding proteins [68].
4.2. Kainate Receptors
4.2.1. Presynaptic KARs
The five subtypes of KAR subunits (GluK1–5) co-assemble in various combinations, probably
as heteromers [69,70]. Similarly to AMPA subunits, the mRNAs of KAR subunits are subject to
modifications, such as alternative splicing and editing, resulting in a relatively large pharmacological
heterogeneity of the KARs [69–73]. Levels of the kainate receptor mRNA in the granule cell layer
of the dentate fascia have been decreased significantly in limbic seizures [74]. The presence of KAR
mRNA in dentate granule cells predicts the presence of functional KARs in mossy fiber axon terminals.
The literature data has supported that the mossy fiber synapses contain abundant presynaptic KARs:
in the CA3 of the hippocampus, LTP is a presynaptic phenomenon [72]. These KARs probably contain
the GluK2 and GluK3 subunits, which can facilitate the glutamate release through Ca2+ influx and
facilitate the release of Ca2+ from intraaxonal pools [75]. These presynaptic receptors presumably
contain the subunit GluK5 as well, since the GluK5 (and GluK4) subunits are key proteins in directing
KARs to synapses [76]. The importance of the GluK5 subunit in epileptogenesis was suggested by the
histoblots, which proved the significant decrease of the GluK5 density following 4-AP seizures in the
SLUC of the CA3, according to the termination area of the mossy fibers [13]. However, the role and
presence of presynaptic GluK5 in epileptogenesis needs further investigations.
The downregulation of the presynaptic kainate receptors in Neto-knockout animals increased
network inhibition, suggesting the role of presynaptic, interneuron KARs in hippocampal gamma
oscillations [77]. Investigations of GluK2 overexpression and knockout animals have suggested that
the presence of hippocampal GluK2 promoted seizure activity [78,79]. The GluK1 mRNA is mainly
expressed in the glutamatergic principal cells of the hippocampus, while GluK2 mRNA expression was
detected in GABAergic interneurons [80]. Presynaptic GluK2-containing KARs modulate glutamate
release not only via ionotropic but also via metabotropic modes [69,70]. The possible epileptogenic
effects of GluK2 and GluK5 were proved in hippocampal slices with mossy fiber sprouting in
the dentate fascia: pharmacological inhibition of the two subunits significantly reduced the ictal
discharges [79]. Similarly, 7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile (CNQX) inhibition
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of KARs prevented high-frequency hippocampal oscillations in animal seizures [81]. The epileptogenic
effects of the presynaptic KARs may also manifest through the decrease of inhibition, because kainic
acid was reducing GABA release in the hippocampus, and GABAergic interneurons express KARs
that regulate their activity [75,79,80].
4.2.2. Postsynaptic KARs
It is likely that not only the presynaptic mossy fiber axons but also the postsynaptic densities
of the CA3 pyramidal cells contain the necessary KAR subunits [30,36,73]. Postsynaptically, the
KARs mediate synaptic transmission as nonselective cation channels, and they may be involved
in the regulation of neuronal plasticity, such as LTP, because they are permeable to Ca2+ [69–71].
Postsynaptic KARs may also be involved in the neurotoxicity of glutamate in the CA3 region of
the hippocampus [70,71,73]. The CA3 neurons suffer damage in chronic seizures [15]. This CA3
neurodegeneration [15] might be the aftermath of the postsynaptic Ca2+-permeable KARs present
in these pyramidal cells, and that of the chronic Glu release from the sprouted/ectopic mossy
axons [50,53,71,75,82]. The presence of GluK4-5 subunits and their scaffolding proteins in presynaptic
mossy axons and postsynaptic spines have been detected with immunogold methods in the CA3
region [30,36]. According to recent reviews, KARs play an essential role in the dentate fascia in chronic,
recurrent seizures, mediating the ictal electrophysiological phenomena coupled to reactive plasticity
during mossy fiber sprouting into the inner molecular layer (IML) [50,53,75,82]. The sprouting of
the mossy fiber system is targeting not only the IML, the hilus, and the SLUC of CA3, but also the
infrapyramidal layer of the CA3 close to the hilus, or the CA4 [53,75,82]. The question arises as to
whether KARs were present in the postsynaptic elements, the sprouting mossy fibers, or both in
the reorganized CA3, CA4, and dentate fascia [50,53,75,82]. This issue needs further investigation,
as having information on the subunit composition of the receptors in the sprouted mossy fibers and in
their postsynaptic targets could enable better control of these chronic seizures.
4.3. NMDA Receptors
The functional NMDA channels are heteromers consisting of two obligatory GluN1 subunits
and the other two associated subunits of the GluN2A-D and GluN3A-B subtypes [1,3,6,48,58].
The obligatory GluN1 subunit binds glycine and D-serine, and is widely expressed in CNS
neurons [48]. The GluN2A-D subunits bind Glu and determine the potency of Glu and the
Ca2+-permeability of the NMDAR [48]. These subunits are coded by separate genes: GRIN1,
GRIN2A-D, and GRIN3A-B [1,18,58]. It has been shown recently that mutations of the GRIN2A
gene are not rare in epileptic patients [83,84], and that the mutations cause significant functional
alterations of the NMDA receptor [84]. Concerning the functional properties of the heteromeric
complexes, it is known that the GluN2 subunits are important in channel gating, opening, agonist
sensitivity, and deactivation kinetics [1,48,57,58,84]. The GluN2B subunit is also important during
synaptogenesis and synaptic plasticity [38,39,48]. The receptors containing GluN2A are located mainly
in synaptic densities, whilst the GluN2B subunit is supposed to be present also in extrasynaptic NMDA
receptors [6,32,39]. Interestingly, destruction of the LEC (deafferentation of the hippocampus) increased
the amount of GluN2B subunit in the deafferented CA1 and dentate fascia, probably indicating the
presence of non-synaptic NMDA receptors containing GluN2B receptor subunits [12,32].
Animal experiments have proven the reactive plasticity of NMDAR subunits in hippocampal
epileptogenesis [13,15,85]. Experimental status epilepticus increased GluN1 containing synapses in the
dentate fascia [85]. Hypoxic seizures in young rats significantly elevated the hippocampal expression
of GluN3 two to four days after the convulsions [86]. Pilocarpine-induced status epilepticus has been
found to induce a significant increase of NMDA receptors in dentate granule cells and CA3 pyramidal
neurons [38]. The subunit pharmacology experiments have revealed that the GluN2B subunit was
responsible for the augmentation of the excitatory activity in these animals [38]. The increase of the
GluN2B/GluN2A ratio was also detected in epileptic human brain samples [87]. The phosphorylation
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of the GluN2 subunit was significantly elevated in animal epilepsy, indicating the increase of the
turnover of the subunits [88]. Pentylenetetrazole-induced status epilepticus significantly increased
GluN1 and GluN2A total RNA levels isolated from the hippocampus one day after the convulsive
event [89]. On the other hand, seven days following pilocarpine convulsions, GluN1 and GluN2A
RNAs were significantly downregulated, in comparison to the controls [63]. Seizures induced by
intrahippocampal kainic acid first (three days after kainic acid injection) decreased, and then elevated
the GluN1 expression in the dentate fascia [90]. An increase of GluN1-like immunoreactivity has been
detected in the neurons of the rat hippocampus shortly after the SE, indicating that neurons regulate
the receptor traffic according to the synaptic activity [85].
Hippocampal regions display different vulnerability in epilepsy [91]. The CA1 region is among the
hippocampal areas where extensive neuronal death was detected in epileptic patients [91]. The damage
of the CA1 area may begin with the lasting activation of postsynaptic Ca2+-permeable NMDARs [3,9].
The main excitatory afferents of the CA1 originate from the entorhinal cortex (perforant path) and from
the CA3 pyramidal cells (Schaffer collaterals) [92]. These excitatory synapses utilize presynaptic and
postsynaptic NMDARs [93]. The literature data has proved that the subunit composition of NMDA
receptors largely depends on the presynaptic activity [93]; therefore, the synaptic layers display
different aggregates of NMDAR subunits [93]. Since the epileptic electrophysiological processes can
be inhibited by NMDA antagonists [94], we think that the synapses in the SR and SL develop reactive
plasticity in seizure conditions: the Ca2+-permeable NMDARs and AMPARs will be segregated in these
layers during pathological conditions (Figure 3). High-frequency stimulation and epileptic activity
have long-term impacts on these subunit assemblies: the expression [13,15,63], the trafficking [38,85],
and the scaffolding molecules [95] are equally affected. The strong excitatory input on the proximal
dendritic arborization of the pyramidal cells will maintain the remodeling of NMDARs [13,15,93].
We can conclude that the NMDARs are regulated differentially during convulsions: they are
upregulated [89] in the acute phase and downregulated later, in the chronic phase of the disease [63],
although the dynamics of the changes depended on the type of the experiment [85,86,89]. It is not
known if the chronic downregulation [63] was just reflecting the neuronal degeneration, i.e., fewer
neurons contain fewer NMDA receptors. The high frequency stimuli increased the amount of GluN1,
GluN2A, and GluN2B subunits [86,88,89] by influencing the translation and the trafficking [85,95].
We do not know to what extent these subunit alterations are involving the presynaptic and the
postsynaptic NMDARs: both NMDARs play important roles in long-term alterations [58] and probably
in neurotoxicity, too. Although at this time it is not possible to draw firm conclusions as to the
pathogenetic role of the GluN2A and GluN2B subunits in human epilepsy, we have to note that clinical
observations with positron emission tomography have indicated the significant increase of NMDA
receptor ligand binding in human focal epilepsies [96]. Although the increase of ligand binding [96]
could have been the consequence of the appearance of extrasynaptic or non-neuronal NMDARs [32],
these firm observations on animal and human tissues point toward the crucial significance of NMDARs
in epilepsy.
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Figure 3. Pictorial summary of the functional significance of hippocampal ionotropic glutamate
receptors (iGluRs) in epilepsy. Two regions of the Ammon’s horn (CA1 and CA3) and the dentate fascia
are depicted. The pathogenetic importance of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid (AMPA), kainate receptor (KAR), and N-methyl-D-aspartate (NMDA) subunit assemblies is shown
through the letter size and the red glow around them. Layers in CA1: (1) stratum moleculare (SM);
(2) stratum lacunosum (SL); (3) stratum radiatum (SR); (4) stratum pyramidale; (5) stratum oriens
(SO) [92]. Layers in CA3: (1) stratum moleculare (SM); (2) stratum radiatum (SR); (3) stratum lucidum
(SLUC, modified after [92]); (4) stratum pyramidale; (5) stratum oriens (SO); (5a) infrapyramidal
layer containing sprouted mossy axons (modified after [92]). Layers in the dentate fascia: (1) stratum
moleculare (SM); (1a) inner molecular layer (IML), where sprouted mossy axons are present; (2) stratum
granulosum; (3) hilus of the dentate fascia, where sprouting is present, too [50].
5. Conclusions
• Summarizing our own results and the literature data, we can conclude that the main alteration
of AMPARs during epilepsy is the increase of their Ca2+ permeability. This will be achieved
through the downregulation f the GluA2 subunit at the transcriptional, translational, and/or
post-translational levels. The phospho ylatio /dephosphoryla ion cycles of the subunits are
important too, because phosphorylation alone induces C 2+ permeability and ch nges the
trafficking of the receptor. AMPARs are localized in every region of the hippocampal formation;
therefore, the transformation of AMPARs will affect every region and cell type of the hippocampus
(Figure 3).
• The Ca2+ permeability of KARs contributes to epileptogenesis presynaptically by increasing the
release of Glu, and postsynaptically by increasing intracytoplasmic Ca2+ concentration and the
neurotoxicity of Glu. The KARs have an outstanding role in the DF–CA4–CA3 regions. In chronic
pilocarpine epilepsy, there is an extensive axonal sprouting in these regions, which originates from
the dentate granule cells. Sprouting mossy fibers in the IML, SLUC, and hilus of the dentate fascia
form synapses [97] and probably maintain neurotoxicity through their KAR content (Figure 3).
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• The NMDARs display reactive plasticity in epilepsy; their localization and subunit composition
are subject to changes from the acute phase until the chronic phase of epilepsy. The alterations
of the GluN1 and GluN2 subunits include transcriptional, translational, post-translational,
local phosphorylation, and trafficking changes. According to literature data, the GluN2A and
GluN2B subunits are the most frequently involved. The NMDARs function mainly in the
postsynaptic regions of the CA1 and the ML of the DF, where they may display synaptic and
extrasynaptic localizations. In every case, they mediate the toxic effects of Glu (Figure 3).
• The reactive plasticity of the iGluRs in different hippocampal regions accommodates to neuronal
types (principal neurons/interneurons) and afferent connections (Figure 3). The inhibitory
interneurons of the hippocampus utilize KARs, NMDARs, and Ca2+-permeable AMPA receptors,
and these iGluR combinations may be responsible for the ongoing degeneration of hippocampal
inhibitory interneuron populations in epilepsy [98].
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Abbreviations
AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptor
NMDAR N-methyl-D-aspartate receptor
KAR kainate receptor
iGluR ionotropic glutamate receptor
Glu glutamic acid
GYKI 52466 4-(8-methyl-9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline, AMPAR antagonist
CNQX 7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile, KAR antagonist
NBQX 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzol[f]quinoxaline, AMPAR antagonist
4-AP 4-aminopyridine
CA1, CA2, CA3, CA4 Cornu Ammonis regions in the hippocampal formation
DF dentate fascia
SO stratum oriens
SR stratum radiatum
SLUC stratum lucidum
SL stratum lacunosum
SM stratum moleculare
SE status epilepticus
LTP long-term potentiation
LTD long-term depression
NeuN neuron-specific nuclear protein
LEC lateral entorhinal cortex
rCBF regional cerebral blood flow
NMRI-strain mice NMRI: abbreviated from Naval Medical Research Institute (inbred albino mouse line)
Q/R editing RNA editing at the Q/R site: adenosine is converted into inosine by oxidative
deamination. Q/R editing leads to the exchange glutamine to arginine during translation
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Appendix A
The procedure of histoblotting was described in detail previously [12–14,27]. The antibodies used in
histoblots depicted in Figure 1 are as follows: the pan-AMPA (GluA1-4) antibody was raised in rabbit against
a fusion peptide which has a sequence homology in all AMPA receptor subunits [27,28]. The pan-AMPA antibody
was a gift from Elek Molnar (Bristol University). The anti-GluA2 serum (diluted to 1:200) manufactured by
Chemicon, the monoclonal anti-GluN1 serum (diluted to 1:200) by BD PharMingen and the rabbit anti-GluK5
serum (diluted to 1:200) made by Abcam. The mouse tissues on Figure 2A,B were perfusion-fixed, sectioned at 25
µm thickness and reacted with anti-GluK1 and anti-GluK2 sera manufactured by Alomone Labs. The antibody
was diluted to 1:200 and the binding was visualized with the streptavidin-peroxidase system (Figure 2A) and
secondary antibodies labeled with Alexa Fluor 488 (Molecular Probes) (Figure 2B). The shaping of hippocampal
neurons and the layers’ nomenclature of Figure 3, and in other parts of the text were adopted from Stephan [92].
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